Selank
Cas No.: 129954-34-3
What is Selank?
Selank (threonyl-lysyl-prolyl-arginyl-prolyl-glycyl-proline-diacetate) is a peptide that is an analog of the tuftsin protein. Other names for this formulation include Cеланк, TP-7. The product was initially synthesized at the Russian Academy of Medical Sciences, and its primary action was to relieve anxiety and stress. However, this is not the only profile of the product, as it has found use as a nootropic agent. Examples of other nootropic formulations developed by Russian scientists include Ladasten and Semax.
Application of Selank
Selank is a compound that comprehensively supports the functioning of the nervous system. It increases the body’s resistance to stress, relieves increased nervous tension and anxiety. It normalizes the diurnal rhythm, making it easier to fall asleep, and allows the mind to remain clear during the day.
The product facilitates memorization, improves memory and concentration, cognitive function. First, it facilitates learning and mental work, increases motivation levels and facilitates fast, efficient action. Second, it has a positive effect on mental well-being. It can alleviate the body’s susceptibility to nervous and stressful situations, making it easier to perform daily work duties.
Mechanism of action
Selank modulates the functioning of the nervous system. It affects the expression of BDNF, or brain-derived neurotrophic factor. In addition, it increases levels of such neurotransmitters as serotonin, norepinephrine and dopamine. The product’s mechanism of action also includes activation of gabaergic receptors.
Selanide dosage
The product is administered as an intranasal solution. The recommended dosage of the product is 2-3 doses into each nasal passage, administered three times a day. The best results can be seen during regular use. The recommended duration of use is 10-14 days, supplementation can be repeated after 1-3 weeks.
References:
- Uchakina, O. N. et al. “Immunomodulatory effects of selank in patients with anxiety-asthenic disorders” 2008, Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 108 (5): 71-75; https://pubmed.ncbi.nlm.nih.gov/18577961/
- Anastasiya Volkova et al. “Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission” Front Pharmacol. 2016; 7: 31; https://europepmc.org/article/MED/26924987
- Zozulia AA et al. “[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia].” Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48; https://pubmed.ncbi.nlm.nih.gov/18454096/
